3--tetrahydro-pyran | 14278-69-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 氧烷类
• 英文名称: 3--tetrahydro-pyran
• 英文别名: 2-(Oxan-3-yl)oxane
• CAS: 14278-69-4
• 化学式: C₁₀H₁₈O₂
• 分子量: 170.252
• InChiKey: CISDPZZTKDUCON-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  18.5
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• SPIROCYCLIC ETHER DERIVATIVES OF PYRAZOLO[1,5-A]PYRIMIDINE-3-CARBOXAMIDE
  申请人：Boehringer Ingelheim International GmbH

  公开号：EP3156405A1

  公开（公告）日：2017-04-19

  The invention relates to Spirocyclic ether derivatives of pyrazolo[1,5-a]pyrimidine-3-carboxyamide of general formula (I) which are inhibitors of phosphodiesterase 2, useful in treating central nervous system diseases and other diseases. In addition, the invention relates to processes for preparing pharmaceutical compositions as well as processes for manufacture the compounds according to the invention.

  本发明涉及通式（I）的吡唑并[1,5-a]嘧啶-3-羧酰胺螺环醚衍生物，它是磷酸二酯酶 2 的抑制剂，可用于治疗中枢神经系统疾病和其他疾病。 此外，本发明还涉及制备药物组合物的工艺以及根据本发明制造化合物的工艺。
• Cyclic ether derivatives of pyrazolo[1,5-a]pyrimidine-3-carboxyamide
  申请人：Boehringer Ingelheim International GmbH

  公开号：US10479794B2

  公开（公告）日：2019-11-19

  The invention relates to Spirocyclic ether derivatives of pyrazolo[1,5-a]pyrimidine-3-carboxyamide of general formula (I) which are inhibitors of phosphodiesterase 2, useful in treating central nervous system diseases and other diseases. In addition, the invention relates to processes for preparing pharmaceutical compositions as well as processes for manufacture the compounds according to the invention.

  本发明涉及通式（I）的吡唑并[1,5-a]嘧啶-3-羧酰胺螺环醚衍生物，它是磷酸二酯酶 2 的抑制剂，可用于治疗中枢神经系统疾病和其他疾病。此外，本发明还涉及制备药物组合物的工艺以及根据本发明制造化合物的工艺。
• CYCLIC ETHER DERIVATIVES OF PYRAZOLO[1,5-A]PYRIMIDINE-3-CARBOXYAMIDE
  申请人：Boehringer Ingelheim International GmbH

  公开号：US20180134720A1

  公开（公告）日：2018-05-17

  The invention relates to Spirocyclic ether derivatives of pyrazolo[1,5-a]pyrimidine-3-carboxyamide of general formula (I) which are inhibitors of phosphodiesterase 2, useful in treating central nervous system diseases and other diseases. In addition, the invention relates to processes for preparing pharmaceutical compositions as well as processes for manufacture the compounds according to the invention.